| 赵 静,王奇金,魏 苏,李庆凤,汝 燕.硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性分析[J].,2017,17(10):1931-1933 |
| 硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性分析 |
| Analysis of Efficacy and Safety of Lipoic Acid and Valsartan in the Treatment of the Early Diabetic Nephropathy |
| 投稿时间：2016-07-22 修订日期：2016-08-19 |
| DOI：10.13241/j.cnki.pmb.2017.10.035 |
| 中文关键词: 硫辛酸 缬沙坦 糖尿病肾病 氧化应激 尿蛋白 |
| 英文关键词: Lipoic acid Valsartan Diabetic nephropathy Oxidative stress Urinary protein |
| 基金项目: |
|
| 摘要点击次数: 249 |
| 全文下载次数: 107 |
| 中文摘要: |
| 摘要 目的：探讨硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性。方法：选取了80例糖尿病肾病患者，按随机数字表法分为两组，对照组(39例) 给予缬沙坦治疗，观察组(41例) 给予缬沙坦和硫辛酸治疗。通过观察并记录患者治疗前后超敏C反应蛋白(hs-CRP)，尿蛋白排泄率(UAER)，尿β2微球蛋白(β2-MG)，血清丙二醛(MDA)，总抗氧化能力(T-AOC)，超氧化物歧化酶(SOD)水平及治疗期间不良反应情况，评价硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性。结果：治疗前两组hs-CRP，UEAR，β2-MG差异无统计学意义(P>0.05)，经2个疗程药物治疗后两组各指标均明显降低。使用硫辛酸联合缬沙坦治疗的患者，治疗后上述指标降幅更明显(P<0.05)，治疗前，两组SOD、MDA、T-AOC水平差异无统计学意义(P>0.05)，治疗后两组SOD、T-AOC水平均显著增加，MDA水平显著降低(P<0.05)。组间比较，观察组SOD、T-AOC水平高于对照组，MDA水平低于对照组(P<0.05)；治疗期间，两组不良反应率无统计学意义(P>0.05)。结论：硫辛酸联合缬沙坦能显著减少糖尿病肾病患者尿蛋白水平，改善机体氧化应激状态，用药安全，值得临床推广使用。 |
| 英文摘要: |
| ABSTRACT Objective: To discuss the efficacy and safety of lipoic acid and valsartan in the treatment of the early diabetic nephropathy. Methods: 80 patients with diabetic nephropathy were randomly divided into two groups. The patients in control group (39 cases) were given valsartan, and the patients in observation group(41 cases) were given valsartan and lipoic acid.The efficacy and safety of lipoic acid and valsartan in the treatment of the early diabetic nephropathy was evaluated by UAER, hs-CRP, β2-MG, SOD, T-AOC, MDA levels and the incidence of adverse reactions were detected during treatment. Results: Before treatment, there were no statistical significance in the level of hs-CRP, UEAR, β2-MG between two groups (P>0.05). After 2 courses of treatment, the indexes were decreased in two groups (P<0.05). After treating with lipoic acid and valsartan, the indexes were decreased obviously (P<0.05). Before treatment, there were no statistical significance in the level of SOD, MDA, T-AOC between two groups (P>0.05). After treatment, the SOD, T-AOC level was increased in two groups (P<0.05), and the MDA level was decreased in two groups (P<0.05). The SOD and T-AOC level of observation group was higher than that of the control group and the MDA level of observation group was lower than that of the control group(P<0.05). There were no statistical significance in incidence of adverse reactions between two groups (P>0.05). Conclusion: The combination of lipoic acid and valsartan can significantly reduce the level of urinary protein and improve the oxidative stress state in patients with diabetic nephropathy with good safety, worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
